caa a22 4500 386389454 CHVBK 20180307112109.0 cr unu---uuuuu 161130s1989 xx s 000 0 eng 10.1017/S0269727000010708 doi S0269727000010708 pii (NATIONALLICENCE)cambridge-10.1017/S0269727000010708 Stewart Helen J. Scottish Cancer Trials Office (MRC), The Medical School, Teviot Place, Edinburgh, EH8 9AG, Scotland, U.K. Clinical experience in the use of the antioestrogen tamoxifen in the treatment of breast cancer [Elektronische Daten] [Helen J. Stewart] The use of tamoxifen in the treatment of both metastatic and primary breast cancer is reviewed. In metastatic disease, tamoxifen slows progression in at least one-third of patients and is now the preferred first systemic therapy. Results from the larger trials of adjuvant tamoxifen are reviewed in relation to total dose and receptor status. It is suggested that variations in total dose may account for the variable results reported. Although benefit is not confined to those with tumours which are oestrogen-receptor (ER)-positive, the greatest chance of increasing disease-free survival would seem to be in those with high ER levels. Duration of tamoxifen and its effect within defined ER categories, with and without chemotherapy, are areas requiring further study by direct comparison. Copyright © Royal Society of Edinburgh 1989 Oestrogen Deprivation - Antioestrogens nationallicence Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences Royal Society of Edinburgh Scotland Foundation 95(1989), 231-237 0269-7270 95<231 1989 95 PRB https://doi.org/10.1017/S0269727000010708 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S0269727000010708 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Stewart Helen J. Scottish Cancer Trials Office (MRC), The Medical School, Teviot Place, Edinburgh, EH8 9AG, Scotland, U.K NATIONALLICENCE 773 0- Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences Royal Society of Edinburgh Scotland Foundation 95(1989), 231-237 0269-7270 95<231 1989 95 PRB CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge